NCT02065349View on ClinicalTrials.gov

A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety

PHASE2CompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

February 24, 2014

Primary Completion Date

February 13, 2015

Study Completion Date

February 13, 2015

Conditions
Post-Herpetic Neuralgia (PHN)Neuropathic PainPainful Diabetic Peripheral Neuropathy (PDPN)
Interventions
DRUG

ASP8477

oral

DRUG

Placebo

oral

Trial Locations (17)

12000

Site: CZ42014, Prague

41460

Site: DE49005, Neuss

50937

Site: DE49003, Cologne

77900

Site: CZ42011, Olomouc

561 01

Site: CZ42003, Choceň

517 14

Site: CZ42004, Litomyšl

516 01

Site: CZ42001, Rychnov nad Kněžnou

710 00

Site: CZ42002, Slezská Ostrava

15-950

Site: PL48003, Bialystok

60-773

Site: PL48004, Poznan

61-655

Site: PL48001, Poznan

87-100

Site: PL48002, Torun

00-465

Site: PL48005, Warsaw

G12OYN

Site: GB44001, Glasgow

IP45PD

Site: GB44003, Ipswich

SE17EH

Site: GB44006, London

M320UT

Site: GB44002, Manchester

All Listed Sponsors
lead

Astellas Pharma Europe B.V.

INDUSTRY

NCT02065349 - A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety | Biotech Hunter | Biotech Hunter